News & Updates
Excerpt from the Press Release: WILMINGTON, Del.–(BUSINESS WIRE)–Incyte (Nasdaq:INCY) today announced that the Phase 3 RUXCOVID study evaluating the safety and efficacy of ruxolitinib (Jakafi®), a JAK1/JAK2 inhibitor, plus standard-of-care (SoC) as a treatment for patients 12 years and older with COVID-19 associated cytokine storm did not meet its primary endpoint. Initial data show that…
Read More
Excerpt from the Article: STONY BROOK, NY, December 18, 2020 – A new study that records patient volume at Stony Brook Medicine’s Bariatric and Metabolic Weight Loss Center reveals that follow-up telehealth visits are highly effective during the COVID-19 pandemic. The study, published in the December issue of the Annals of Surgery, serves as an…
Read More
Excerpt from the Article: The famous patient Henry Molaison (long known as H.M.) suffered damage to his hippocampus after a surgical attempt to cure his epilepsy. As a result, he had anterograde amnesia, which meant that things he learned never made it past his short-term memory. Though his memories of childhood remained intact, H.M. might…
Read More
Excerpt from the Article: A pioneering new eye test, developed by scientists at UCL in collaboration with the Western Eye Hospital, London, may predict wet AMD, a leading cause of severe sight loss, three years before symptoms develop. Researchers hope their test could be used to identify the disease early enough so that treatment can…
Read More
Excerpt from the Press Release: BOSTON–(BUSINESS WIRE)–PureTech Health plc (LSE: PRTC, Nasdaq: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, today announced the initiation of its Phase 1 clinical trial of LYT-200 for the potential treatment of metastatic solid tumors that are…
Read More
Yesterday, we held our sixth virtual networking meeting in our ongoing series called Ask us Anything In Clinical Research. This was our Holiday meeting where we reflected on the challenges we all faced during 2020, and discuss what the clinical trials will be like in 2021 and beyond. Thank you to everyone who attended including,…
Read More
Excerpt from the Press Release: SAN DIEGO, Dec. 10, 2020 /PRNewswire/ — Ambrx Inc., a clinical-stage biopharmaceutical company focused on developing Precision Biologics using an expanded genetic code, provided a clinical update on their lead program ARX788, a homogeneous and highly stable, site-specific antibody drug conjugate (ADC) targeting HER2 positive cancers. “As presented at the 2020…
Read More
Excerpt from the Press Release: CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN and MUNICH, Germany, Dec. 08, 2020 (GLOBE NEWSWIRE) — Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies, and Alnylam Pharmaceuticals, Inc. (“Alnylam”), the leading…
Read More
Excerpt from the Press Release: PHILADELPHIA— Knocking out a protein known to stifle T cell activation on CAR T cells using the CRISPR/Cas9 technology enhanced the engineered T cells’ ability to eliminate blood cancers, according to new preclinical data from researchers in the Perelman School of Medicine at the University of Pennsylvania and Penn’s Abramson…
Read More
Excerpt from the Press Release: PLYMOUTH MEETING, Pa. and SUZHOU, China, Dec. 10, 2020 /PRNewswire/ — INOVIO (NASDAQ: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, and Advaccine Biopharmaceuticals Suzhou Co., Ltd. (“Advaccine”), an emerging biotech company with next-generation technology in vaccines –…
Read MoreRequest Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?